Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous polymerized house dust mite allergen immunotherapy versus placebo for rhinitis/rhinoconjunctivitis and asthma
2018-004262-34Phase 2Active
- Sponsor
- Inmunotek
- Start
- Jan 2020
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of MM09-I and MM09-II in house dust mite allergy, allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and 1 more (2 arms), sponsored by Inmunotek. Primary endpoint: Combined symptom and medication score. Started Jan 2020; status: active.
02
Drugs
MM09-IMM09-II
03
Conditions
house dust mite allergyallergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2018-004262-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004262-34.